Molecular pathology of endocrine gland tumors: genetic alterations and clinicopathologic relevance

被引:0
作者
Antonio De Leo
Martina Ruscelli
Thais Maloberti
Sara Coluccelli
Andrea Repaci
Dario de Biase
Giovanni Tallini
机构
[1] University of Bologna,Department of Medical and Surgical Sciences (DIMEC)
[2] IRCCS Azienda Ospedaliero-Universitaria di Bologna,Solid Tumor Molecular Pathology Laboratory
[3] IRCCS Azienda Ospedaliero-Universitaria di Bologna,Division of Endocrinology and Diabetes Prevention and Care
[4] University of Bologna,Department of Pharmacy and Biotechnology (FaBit)
来源
Virchows Archiv | 2024年 / 484卷
关键词
Molecular pathology; Endocrine gland tumors; PitNET; Thyroid tumors; Parathyroid tumors; Adrenal cortical tumors; Paraganglionic tumors  ;
D O I
暂无
中图分类号
学科分类号
摘要
Tumors of the endocrine glands are common. Knowledge of their molecular pathology has greatly advanced in the recent past. This review covers the main molecular alterations of tumors of the anterior pituitary, thyroid and parathyroid glands, adrenal cortex, and adrenal medulla and paraganglia. All endocrine gland tumors enjoy a robust correlation between genotype and phenotype. High-throughput molecular analysis demonstrates that endocrine gland tumors can be grouped into molecular groups that are relevant from both pathologic and clinical point of views. In this review, genetic alterations have been discussed and tabulated with respect to their molecular pathogenetic role and clinicopathologic implications, addressing the use of molecular biomarkers for the purpose of diagnosis and prognosis and predicting response to molecular therapy. Hereditary conditions that play a key role in determining predisposition to many types of endocrine tumors are also discussed.
引用
收藏
页码:289 / 319
页数:30
相关论文
共 321 条
[1]  
Rindi G(2022)Overview of the 2022 WHO classification of neuroendocrine neoplasms Endocr Pathol 33 115-154
[2]  
Mete O(2013)Familial isolated pituitary adenomas (FIPA) and the pituitary adenoma predisposition due to mutations in the aryl hydrocarbon receptor interacting protein (AIP) gene Endocr Rev 34 239-277
[3]  
Uccella S(2008)Clinical, genetic, and histopathologic investigation of CDC73-related familial hyperparathyroidism Endocr Relat Cancer 15 1115-1126
[4]  
Beckers A(2017)MEN4 and CDKN1B mutations: the latest of the MEN syndromes Endocr Relat Cancer 24 T195-T208
[5]  
Aaltonen LA(2019)Clinical features of multiple endocrine neoplasia type 4: novel pathogenic variant and review of published cases J Clin Endocrinol Metab 104 3637-3646
[6]  
Daly AF(2019)Ten years of DICER1 mutations: provenance, distribution, and associated phenotypes Hum Mutat 40 1939-1953
[7]  
Karhu A(2012)MAX mutations cause hereditary and sporadic pheochromocytoma and paraganglioma Clin Cancer Res 18 2828-2837
[8]  
Masi G(2012)MAX and MYC: a heritable breakup Cancer Res 72 3119-3124
[9]  
Barzon L(2021)Multiple endocrine neoplasia type 1: latest insights Endocr Rev 42 133-170
[10]  
Iacobone M(2007)Guidelines for the diagnosis and management of individuals with neurofibromatosis 1 J Med Genet 44 81-88